SV2018005801A - 1h-pirazolo[4,3-b]piridinas como inhibidores de pde 1 - Google Patents

1h-pirazolo[4,3-b]piridinas como inhibidores de pde 1

Info

Publication number
SV2018005801A
SV2018005801A SV2018005801A SV2018005801A SV2018005801A SV 2018005801 A SV2018005801 A SV 2018005801A SV 2018005801 A SV2018005801 A SV 2018005801A SV 2018005801 A SV2018005801 A SV 2018005801A SV 2018005801 A SV2018005801 A SV 2018005801A
Authority
SV
El Salvador
Prior art keywords
pirazolo
piridines
pde inhibitors
inhibitors
disorders
Prior art date
Application number
SV2018005801A
Other languages
English (en)
Inventor
Jan Kehler
Karsten Juhl
Mauro Marigo
Pablo Jorge Vieira Vital
Mikkel Jessing
Morten Langgärd
Lars Kyhn Rasmussen
Carl Martin Sebastián Clementson
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of SV2018005801A publication Critical patent/SV2018005801A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA 1H-PIRAZOLO[4,3-B]PIRIDIN-7-AMINAS DE FÓRMULA (I) COMO INHIBIDORES DE PDE1 Y SU USO COMO MEDICAMENTO, EN PARTICULAR PARA EL TRATAMIENTO DE TRASTORNOS NEURODEGENERATIVOS Y TRASTORNOS PSIQUIÁTRICOS (VER FÓRMULA)
SV2018005801A 2016-07-04 2018-12-14 1h-pirazolo[4,3-b]piridinas como inhibidores de pde 1 SV2018005801A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201600397 2016-07-04
DKPA201600612 2016-10-11
DKPA201700236 2017-04-04

Publications (1)

Publication Number Publication Date
SV2018005801A true SV2018005801A (es) 2019-02-13

Family

ID=60806291

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2018005801A SV2018005801A (es) 2016-07-04 2018-12-14 1h-pirazolo[4,3-b]piridinas como inhibidores de pde 1

Country Status (38)

Country Link
US (7) US10034861B2 (es)
EP (2) EP3689874A1 (es)
JP (1) JP7096171B2 (es)
KR (2) KR102576888B1 (es)
CN (1) CN109311872B (es)
AU (1) AU2017291794C1 (es)
CA (1) CA3026857A1 (es)
CL (1) CL2019000010A1 (es)
CO (1) CO2018013803A2 (es)
CR (1) CR20190003A (es)
CY (1) CY1122957T1 (es)
DK (1) DK3478681T3 (es)
DO (1) DOP2018000266A (es)
EC (1) ECSP18093944A (es)
ES (1) ES2784655T3 (es)
GE (1) GEP20207172B (es)
HR (1) HRP20200440T1 (es)
HU (1) HUE048576T2 (es)
IL (1) IL263511B (es)
JO (1) JO3819B1 (es)
LT (1) LT3478681T (es)
MA (1) MA52593A (es)
ME (1) ME03672B (es)
MX (1) MX2018015734A (es)
MY (1) MY197140A (es)
PE (1) PE20190339A1 (es)
PH (1) PH12018502604A1 (es)
PL (1) PL3478681T3 (es)
PT (1) PT3478681T (es)
RS (1) RS60072B1 (es)
RU (1) RU2759380C2 (es)
SG (1) SG11201810965YA (es)
SI (1) SI3478681T1 (es)
SV (1) SV2018005801A (es)
TW (1) TWI763683B (es)
UA (1) UA122824C2 (es)
WO (1) WO2018007249A1 (es)
ZA (1) ZA201808257B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10034861B2 (en) * 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
JOP20190126A1 (ar) 2016-12-22 2019-05-28 H Lundbeck As بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
HUE057202T2 (hu) * 2017-12-14 2022-04-28 H Lundbeck As Kombinációs kezelések 1H-pirazolo[4,3-b]piridinek alkalmazásával
AR113926A1 (es) * 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
US11535611B2 (en) 2017-12-20 2022-12-27 H. Lundbeck A/S Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors
US10766893B2 (en) 2017-12-20 2020-09-08 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
TW201927784A (zh) * 2017-12-20 2019-07-16 丹麥商Ｈ 朗德貝克公司 作為pde1抑制劑之大環
CN113966217A (zh) * 2019-06-14 2022-01-21 达萨玛治疗公司 Sarm1抑制剂
CN112390750B (zh) * 2020-11-11 2022-03-01 常州大学 作为选择性磷酸二酯酶2抑制剂的喹啉酮类化合物及其制备方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
DE19942474A1 (de) * 1999-09-06 2001-03-15 Merck Patent Gmbh Pyrazolo[4,3-d]pyrimidine
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
GB0230045D0 (en) * 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
RU2348633C2 (ru) * 2002-12-23 2009-03-10 Глаксо Груп Лимитед ПИРАЗОЛО[3,4-b]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗ
DE602005011286D1 (en) 2004-07-05 2009-01-08 Astellas Pharma Inc Pyrazolopyridinderivate
KR100710430B1 (ko) * 2004-08-24 2007-04-24 삼성코닝 주식회사 면광원 장치 및 이를 갖는 백 라이트 유닛
WO2006044821A1 (en) 2004-10-19 2006-04-27 Sb Pharmco Puerto Rico Inc. Crf receptor antagonists and methods relating thereto
EP1844201B1 (en) 2005-02-04 2016-08-24 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
RU2402549C3 (ru) 2005-04-14 2022-03-10 Оцука Фармасьютикал Ко., Лтд. Пиперазин-замещенные бензотиофены для лечения психических расстройств
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
NZ567540A (en) 2005-12-22 2010-07-30 Newron Pharm Spa 2-Phenylethylamino derivatives as calcium and/or sodium channel modulators
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
WO2008070095A1 (en) 2006-12-05 2008-06-12 Intra-Cellular Therapies, Inc. Novel uses
EP2124944B1 (en) * 2007-03-14 2012-02-15 Ranbaxy Laboratories Limited Pyrazolo[3,4-b]pyridine derivatives as phosphodiesterase inhibitors
EP2367431B1 (en) 2008-12-06 2015-08-05 Intra-Cellular Therapies, Inc. Organic compounds
CA2765099A1 (en) 2009-06-10 2010-12-16 New York University Phosphorylated tau peptide for use in the treatment of tauopathy
PL3339323T3 (pl) 2010-08-12 2020-05-18 Eli Lilly And Company Przeciwciała przeciwko peptydowi N3pGlu amyloidu beta i ich zastosowania
US9499610B2 (en) 2011-04-08 2016-11-22 H. Lundbeck A/S Antibodies specific to pyroglutamated Aβ
US9499535B2 (en) 2011-04-21 2016-11-22 Origenis Gmbh Kinase inhibitors
CN104024258B (zh) * 2011-09-01 2017-02-15 霍夫曼-拉罗奇有限公司 吡咯并吡嗪激酶抑制剂
CA2866302A1 (en) 2012-03-19 2013-09-26 Abide Therapeutics, Inc. Carbamate compounds and of making and using same
TW201533043A (zh) 2013-04-18 2015-09-01 Lundbeck & Co As H 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物
AU2014284616B2 (en) * 2013-06-21 2019-02-28 Zenith Epigenetics Ltd. Novel bicyclic bromodomain inhibitors
UA116023C2 (uk) 2013-07-08 2018-01-25 Ф. Хоффманн-Ля Рош Аг Етинільні похідні як антагоністи метаботропного глутаматного рецептора
EP3035800B1 (en) * 2013-08-22 2019-10-09 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
MA39225A1 (fr) 2014-02-19 2017-04-28 H Lundbeck As 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tétrahydropyridines utilisées en tant qu'inhibiteurs de bace1 dans le traitement de la maladie d'alzheimer
TWI599358B (zh) 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
US20160083400A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic guanidine derivative
US20160083391A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic piperazine derivative
WO2016042775A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic derivative
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
CR20170187A (es) 2014-11-10 2018-02-01 H Lundbeck As 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
JO3458B1 (ar) 2014-11-10 2020-07-05 H Lundbeck As 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
MA40941A (fr) 2014-11-10 2017-09-19 H Lundbeck As 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
JP2018508555A (ja) 2015-03-16 2018-03-29 大日本住友製薬株式会社 二環性イミダゾロ誘導体
TW201643167A (zh) 2015-04-22 2016-12-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之咪唑並三酮
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
US10206909B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
MX2018001699A (es) 2015-08-12 2018-05-07 H Lundbeck As 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidr opiridinas como inhibidores de bace1.
US20180344680A1 (en) 2015-12-08 2018-12-06 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treatment, amelioration, and prevention of diabetes-related skin ulcers
MX2018005767A (es) 2015-12-09 2019-05-16 Ford Global Tech Llc Alerta para dispositivo movil olvidado.
WO2017172795A1 (en) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel compositions and methods
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
JOP20190126A1 (ar) 2016-12-22 2019-05-28 H Lundbeck As بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1
HUE057202T2 (hu) 2017-12-14 2022-04-28 H Lundbeck As Kombinációs kezelések 1H-pirazolo[4,3-b]piridinek alkalmazásával
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
US10766893B2 (en) 2017-12-20 2020-09-08 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
TW201927784A (zh) 2017-12-20 2019-07-16 丹麥商Ｈ 朗德貝克公司 作為pde1抑制劑之大環
US11535611B2 (en) 2017-12-20 2022-12-27 H. Lundbeck A/S Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors

Also Published As

Publication number Publication date
AU2017291794C1 (en) 2022-01-13
IL263511A (en) 2019-01-31
HUE048576T2 (hu) 2020-08-28
US11026924B2 (en) 2021-06-08
MY197140A (en) 2023-05-26
US10034861B2 (en) 2018-07-31
AU2017291794A1 (en) 2018-12-20
WO2018007249A1 (en) 2018-01-11
JOP20180116A1 (ar) 2019-01-30
CN109311872B (zh) 2021-08-20
MX2018015734A (es) 2019-03-21
CR20190003A (es) 2019-05-06
EP3478681B1 (en) 2020-02-26
ECSP18093944A (es) 2019-01-31
US20200375950A1 (en) 2020-12-03
US20190105302A1 (en) 2019-04-11
JO3819B1 (ar) 2021-01-31
KR20220154262A (ko) 2022-11-21
TWI763683B (zh) 2022-05-11
KR102488909B1 (ko) 2023-01-13
US10806718B2 (en) 2020-10-20
KR102576888B1 (ko) 2023-09-08
JP2019524689A (ja) 2019-09-05
US11026923B2 (en) 2021-06-08
ZA201808257B (en) 2020-05-27
CA3026857A1 (en) 2018-01-11
JP7096171B2 (ja) 2022-07-05
CL2019000010A1 (es) 2019-02-22
CN109311872A (zh) 2019-02-05
RU2759380C2 (ru) 2021-11-12
UA122824C2 (uk) 2021-01-06
DOP2018000266A (es) 2019-03-15
GEP20207172B (en) 2020-10-26
KR20190025606A (ko) 2019-03-11
AU2017291794B2 (en) 2021-07-22
PL3478681T3 (pl) 2020-06-15
RS60072B1 (sr) 2020-05-29
CO2018013803A2 (es) 2019-01-18
ES2784655T3 (es) 2020-09-29
TW201806950A (zh) 2018-03-01
MA52593A (fr) 2021-03-17
US20210015794A1 (en) 2021-01-21
RU2018143324A (ru) 2020-08-04
PE20190339A1 (es) 2019-03-07
US20200360343A1 (en) 2020-11-19
SG11201810965YA (en) 2019-01-30
US20180000786A1 (en) 2018-01-04
PT3478681T (pt) 2020-04-03
IL263511B (en) 2020-11-30
PH12018502604A1 (en) 2019-10-21
SI3478681T1 (sl) 2020-04-30
RU2018143324A3 (es) 2020-08-12
HRP20200440T1 (hr) 2020-06-12
US10512632B2 (en) 2019-12-24
CY1122957T1 (el) 2021-10-29
DK3478681T3 (da) 2020-03-23
US20200129480A1 (en) 2020-04-30
EP3478681A1 (en) 2019-05-08
US11491140B2 (en) 2022-11-08
US20210023056A1 (en) 2021-01-28
ME03672B (me) 2020-10-20
EP3689874A1 (en) 2020-08-05
LT3478681T (lt) 2020-04-10

Similar Documents

Publication Publication Date Title
SV2018005801A (es) 1h-pirazolo[4,3-b]piridinas como inhibidores de pde 1
SV2017005419A (es) Triazolopirazinonas como inhibidores de pde1
GT201700223A (es) Imidazopirazinonas como inhibidores de pde 1
SV2018005753A (es) 1,5-dihidro-4h-pirazolo[3,4-d]pirimidin-4-onas y 1,5-dihidro-4h-pirazolo[4,3-c]piridin-4-onas como inhibidores de pde1
PE20160287A1 (es) Inhibidores cristalinos de bromodominos
DOP2019000169A (es) Pirazolo[3,4-b]piridinas e imidazo[1,5-b]piridazinas como inhibidores de pde1
SV2016005220A (es) Quinazolin-thf-aminas como inhibidores de pde1
GT201700016A (es) [1,2,4] triazolo [4,3 -b] piridazinas para su uso en el tratamiento de enfermedades proliferativas
CL2020001550A1 (es) Tratamientos combinados que comprenden la administración de 1h-pirazolo[4,3-b]piridinas.
SV2016005297A (es) Quinazolin-thf-aminas halogenadas como inhibidores de pde1
DOP2016000179A (es) Hexahidrofuropirroles como inhibidores de pde1
EA201892549A1 (ru) ПРИМЕНЕНИЕ 1H-ПИРАЗОЛО[4,3-b]ПИРИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE1
BR112016019511A8 (pt) Inibidores de jak1 para o tratamento de síndromes mielodisplásicas